Ovid Therapeutics
OVID
69 hedge funds and large institutions have $135M invested in Ovid Therapeutics in 2023 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 21 increasing their positions, 15 reducing their positions, and 14 closing their positions.
2,220% more call options, than puts
Call options by funds: $116K | Put options by funds: $5K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
64% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 14
40% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 15
35% more capital invested
Capital invested by funds: $99.8M → $135M (+$34.7M)
15% more funds holding
Funds holding: 60 → 69 (+9)
3.3% more ownership
Funds ownership: 54.85% → 58.15% (+3.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.11M |
| 2 |
State Street
Boston,
Massachusetts
|
+$2.83M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.42M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.26M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$980K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$5.28M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$3.24M |
| 3 |
D.E. Shaw & Co
New York
|
-$787K |
| 4 |
Millennium Management
New York
|
-$704K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$690K |
OVID Hedge Fund Activity: Q2 2023 in Review
69 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q2 2023, worth a combined $135M — up 35% from $99.8M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new OVID positions and 14 closed out — a net gain of 9 holders — while 21 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock, adding an estimated $9.11M. The largest seller was Rubric Capital Management (New York), cutting an estimated $5.28M.
- 69 institutional investors held Ovid Therapeutics (OVID) as of Q2 2023, up from 60 in Q1 2023.
- Funds reported $135M of Ovid Therapeutics stock for Q2 2023, up 35% quarter-over-quarter.
- 23 funds opened new Ovid Therapeutics positions in Q2 2023 and 14 closed out, a net change of +9 holders.
- The largest Ovid Therapeutics buyer in Q2 2023 was BlackRock, an estimated $9.11M added.
- The largest Ovid Therapeutics seller in Q2 2023 was Rubric Capital Management (New York), an estimated $5.28M sold.
Based on aggregated 13F filings for Q2 2023.